VIRUS ENCODING AN ANTI-TCR-COMPLEX ANTIBODY OR FRAGMENT

(19)

(11)

EP 3 389 683 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	03.05.2023 Bulletin 2023/18

(45)	Mention of the grant of the patent:
	29.03.2023 Bulletin 2023/13

(21)	Application number: 16825728.5

(22)	Date of filing: 19.12.2016

(51)

International Patent Classification (IPC):

A61K 35/761^(2015.01)
C07K 14/00^(2006.01)
C07K 16/28^(2006.01)
A61K 38/17^(2006.01)

A61K 35/768^(2015.01)
A61K 39/00^(2006.01)
A61P 35/00^(2006.01)

(52)	Cooperative Patent Classification (CPC):
	A61K 35/761; C07K 16/2803; C07K 14/00; A61K 2039/505; C07K 2317/622; C07K 2317/73; A61K 38/1774; A61K 35/768; A61P 35/00

(86)	International application number:
	PCT/EP2016/081818

(87)	International publication number:
	WO 2017/103291 (22.06.2017 Gazette 2017/25)

(54)	VIRUS ENCODING AN ANTI-TCR-COMPLEX ANTIBODY OR FRAGMENT ANTI-TCR-KOMPLEX-ANTIKÖRPER ODER -FRAGMENT CODIERENDER VIRUS VIRUS CODANT POUR UN ANTICORPS ANTI-COMPLEXE DU TCR OU UN FRAGMENT DE CELUI-CI

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

17.12.2015 GB 201522334
29.04.2016 GB 201607463
10.10.2016 GB 201617207
10.10.2016 GB 201617206

(43)	Date of publication of application:
	24.10.2018 Bulletin 2018/43

(73)	Proprietor: Akamis Bio Limited
	Abingdon, Oxfordshire OX14 3YS (GB)

(72)	Inventors:
	BROMLEY, Alice Claire Noel Abingdon Oxfordshire OX14 4SD (GB) CHAMPION, Brian Robert Abingdon Oxfordshire OX14 4SD (GB)

(74)	Representative: Sterling IP
	Orion House Bessemer Road Welwyn Garden City AL7 1HH Welwyn Garden City AL7 1HH (GB)

(56)

References cited: :

WO-A1-2014/138314
WO-A1-2015/097220
WO-A1-2016/139463

WO-A1-2015/059303
WO-A1-2015/155370
WO-A1-2016/174200

PAUL S ET AL: "TUMOR GENE THERAPY BY MVA-MEDIATED EXPRESSION OF T-CELL-STIMULATING ANTIBODIES", CANCER GENE THERAPY, APPLETON & LANGE, GB, vol. 9, no. 5, 1 May 2002 (2002-05-01), pages 470-477, XP001080563, ISSN: 0929-1903, DOI: 10.1038/SJ.CGT.7700461
STEPHANE PAUL ET AL: "The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 51, no. 11-12, 1 December 2002 (2002-12-01), pages 645-654, XP055355169, Berlin/Heidelberg ISSN: 0340-7004, DOI: 10.1007/s00262-002-0314-2

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).